Your browser doesn't support javascript.
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants
Jing Zhang; Zi Bo Han; Yu Liang; Xue Feng Zhang; Yu Qin Jin; Li Fang Du; Shuai Shao; Hui Wang; Jun Wei Hou; Ke Xu; Ze Hua Lei; Zhao Ming Liu; Jin Zhang; Ya Nan Hou; Ning Liu; Fu Jie Shen; Jin Juan Wu; Xiang Zheng; Xin Yu Li; Xin Li; Wei Jin Huang; Gui Zhen Wu; Ji Guo Su; Qi Ming Li.
  • Jing Zhang; National Vaccine and Serum Institute (NVSI)
  • Zi Bo Han; National Vaccine and Serum Institute (NVSI)
  • Yu Liang; National Vaccine and Serum Institute (NVSI)
  • Xue Feng Zhang; National Vaccine and Serum Institute (NVSI)
  • Yu Qin Jin; National Vaccine and Serum Institute (NVSI)
  • Li Fang Du; National Vaccine and Serum Institute (NVSI)
  • Shuai Shao; National Vaccine and Serum Institute (NVSI)
  • Hui Wang; Beijing Institute of Biological Products Company Limited
  • Jun Wei Hou; National Vaccine and Serum Institute (NVSI)
  • Ke Xu; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC)
  • Ze Hua Lei; National Vaccine and Serum Institute (NVSI)
  • Zhao Ming Liu; National Vaccine and Serum Institute (NVSI)
  • Jin Zhang; Beijing Institute of Biological Products Company Limited
  • Ya Nan Hou; National Vaccine and Serum Institute (NVSI)
  • Ning Liu; National Vaccine and Serum Institute (NVSI)
  • Fu Jie Shen; National Vaccine and Serum Institute (NVSI)
  • Jin Juan Wu; National Vaccine and Serum Institute (NVSI)
  • Xiang Zheng; National Vaccine and Serum Institute (NVSI)
  • Xin Yu Li; National Vaccine and Serum Institute (NVSI)
  • Xin Li; National Vaccine and Serum Institute (NVSI)
  • Wei Jin Huang; National Institute for Food and Drug Control (NIFDC)
  • Gui Zhen Wu; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC)
  • Ji Guo Su; National Vaccine and Serum Institute (NVSI)
  • Qi Ming Li; National Vaccine and Serum Institute (NVSI)
Preprint in English | bioRxiv | ID: ppbiorxiv-486173
ABSTRACT
Large-scale populations in the world have been vaccinated with COVID-19 vaccines, however, breakthrough infections of SARS-CoV-2 are still growing rapidly due to the emergence of immune-evasive variants, especially Omicron. It is urgent to develop effective broad-spectrum vaccines to better control the pandemic of these variants. Here, we present a mosaic-type trimeric form of spike receptor-binding domain (mos-tri-RBD) as a broad-spectrum vaccine candidate, which carries the key mutations from Omicron and other circulating variants. Tests in rats showed that the designed mos-tri-RBD, whether used alone or as a booster shot, elicited potent cross-neutralizing antibodies against not only Omicron but also other immune-evasive variants. Neutralizing antibody titers induced by mos-tri-RBD were substantially higher than those elicited by homo-tri-RBD (containing homologous RBDs from prototype strain) or the inactivated vaccine BBIBP-CorV. Our study indicates that mos-tri-RBD is highly immunogenic, which may serve as a broad-spectrum vaccine candidate in combating SARS-CoV-2 variants including Omicron.
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: bioRxiv Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Preprint